Fig. 1From: Novel bispecific aptamer targeting PD-1 and nucleolin for cancer immunotherapySchematic illustration of the BiApt design. A The structure of BiApt, which was made of an AS1411 aptamer and a PD-1 aptamer coupled together by sticky ends. B Illustration of the proposed mechanism by which BiApt recruits PD-1-positive T cells to nucleolin-positive tumor cellsBack to article page